97 related articles for article (PubMed ID: 20224643)
1. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
[TBL] [Abstract][Full Text] [Related]
3. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
Bretscher C; Marchini A
Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry.
Kulkarni A; Ferreira T; Bretscher C; Grewenig A; El-Andaloussi N; Bonifati S; Marttila T; Palissot V; Hossain JA; Azuaje F; Miletic H; Ystaas LAR; Golebiewska A; Niclou SP; Roeth R; Niesler B; Weiss A; Brino L; Marchini A
Nat Commun; 2021 Jun; 12(1):3834. PubMed ID: 34158478
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells.
Ferreira T; Kulkarni A; Bretscher C; Nazarov PV; Hossain JA; Ystaas LAR; Miletic H; Röth R; Niesler B; Marchini A
Viruses; 2022 May; 14(5):. PubMed ID: 35632759
[TBL] [Abstract][Full Text] [Related]
6. Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application.
Frehtman V; Wohlfarth D; Müller M; Krebs O; Leuchs B
Appl Microbiol Biotechnol; 2023 Aug; 107(15):4777-4787. PubMed ID: 37209160
[TBL] [Abstract][Full Text] [Related]
7. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.
Allaume X; El-Andaloussi N; Leuchs B; Bonifati S; Kulkarni A; Marttila T; Kaufmann JK; Nettelbeck DM; Kleinschmidt J; Rommelaere J; Marchini A
J Virol; 2012 Apr; 86(7):3452-65. PubMed ID: 22258256
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis.
Ferreira T; Kulkarni A; Bretscher C; Richter K; Ehrlich M; Marchini A
Viruses; 2020 Oct; 12(10):. PubMed ID: 33096814
[TBL] [Abstract][Full Text] [Related]
9. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
10. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.
Neulinger-Muñoz M; Schaack D; Grekova SP; Bauer AS; Giese T; Salg GA; Espinet E; Leuchs B; Heller A; Nüesch JPF; Schenk M; Volkmar M; Giese NA
Viruses; 2021 May; 13(6):. PubMed ID: 34071585
[TBL] [Abstract][Full Text] [Related]
11. A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies.
Hartley A; Kavishwar G; Salvato I; Marchini A
Annu Rev Virol; 2020 Sep; 7(1):537-557. PubMed ID: 32600158
[TBL] [Abstract][Full Text] [Related]
12. Immune System Stimulation by Oncolytic Rodent Protoparvoviruses.
Angelova A; Rommelaere J
Viruses; 2019 May; 11(5):. PubMed ID: 31060205
[TBL] [Abstract][Full Text] [Related]
13. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.
Dempe S; Lavie M; Struyf S; Bhat R; Verbeke H; Paschek S; Berghmans N; Geibig R; Rommelaere J; Van Damme J; Dinsart C
Cancer Immunol Immunother; 2012 Nov; 61(11):2113-23. PubMed ID: 22576056
[TBL] [Abstract][Full Text] [Related]
14. Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing.
Goepfert K; Dinsart C; Rommelaere J; Foerster F; Moehler M
Front Oncol; 2019; 9():425. PubMed ID: 31192129
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Hajda J; Leuchs B; Angelova AL; Frehtman V; Rommelaere J; Mertens M; Pilz M; Kieser M; Krebs O; Dahm M; Huber B; Engeland CE; Mavratzas A; Hohmann N; Schreiber J; Jäger D; Halama N; Sedlaczek O; Gaida MM; Daniel V; Springfeld C; Ungerechts G
Clin Cancer Res; 2021 Oct; 27(20):5546-5556. PubMed ID: 34426438
[TBL] [Abstract][Full Text] [Related]
16. Upstream process optimization and micro- and macrocarrier screening for large-scale production of the oncolytic H-1 protoparvovirus.
Wohlfarth D; Frehtman V; Müller M; Vogel M; Phan LMP; Brunecker A; Leuchs B
Appl Microbiol Biotechnol; 2021 Dec; 105(24):9113-9124. PubMed ID: 34782922
[TBL] [Abstract][Full Text] [Related]
17. Viral therapies for glioblastoma and high-grade gliomas in adults: a systematic review.
Wang JL; Scheitler KM; Wenger NM; Elder JB
Neurosurg Focus; 2021 Feb; 50(2):E2. PubMed ID: 33524943
[TBL] [Abstract][Full Text] [Related]
18. Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses.
Vollmers EM; Tattersall P
Virology; 2013 Nov; 446(1-2):37-48. PubMed ID: 24074565
[TBL] [Abstract][Full Text] [Related]
19. The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics.
Angelova A; Rommelaere J; Ungerechts G
Pathogens; 2024 Feb; 13(3):. PubMed ID: 38535528
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Virus-Bearing Neural Stem Cells Safe in High-Grade Glioma.
Cancer Discov; 2021 Sep; 11(9):2123. PubMed ID: 34244213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]